Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-In Capital	Distributions in Excess of Cumulative Earnings	Distributions in Excess of Cumulative Earnings Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity	Total Stockholders' Equity Cumulative Effect, Period of Adoption, Adjustment	Non- Controlling Interests	Non- Controlling Interests Cumulative Effect, Period of Adoption, Adjustment
Balance at beginning of period (in shares) at Dec. 31, 2018			43,749,092
Balance at beginning of period at Dec. 31, 2018	$ 811,041		$ 431	$ 569,407	$ (7,659)		$ 0	$ 562,179		$ 248,862
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issuance (in shares)			21,462,986
Common stock issuance	423,687		$ 215	423,472				423,687
Costs related to issuance of common stock	(13,901)			(13,901)				(13,901)
Conversion of equity in Secondary Offering, (in shares)			18,502,705
Conversion of equity in Secondary Offering	0		$ 185	237,795				237,980		(237,980)
Other comprehensive income (loss)	(2,905)						(1,949)	(1,949)		(956)
Share-based compensation expense (in shares)			46,368
Share-based compensation expense	4,115		$ 7	4,108				4,115
Unit-based compensation expense	2,162			2,162				2,162
Dividends declared on common stock and OP Units	(70,111)				(61,667)			(61,667)		(8,444)
Net income	48,025				41,844			41,844		6,181
Balance at end of period (in shares) at Dec. 31, 2019			83,761,151
Balance at end of period at Dec. 31, 2019	$ 1,202,113	$ (188)	$ 838	1,223,043	(27,482)	$ (187)	(1,949)	1,194,450	$ (187)	7,663	$ (1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	Accounting Standards Update 2016-13 [Member]
Common stock issuance (in shares)			22,554,057
Common stock issuance	$ 477,799		$ 225	477,574				477,799
Costs related to issuance of common stock	(18,154)			(18,154)				(18,154)
Other comprehensive income (loss)	(35,445)						(35,232)	(35,232)		(213)
Share-based compensation expense (in shares)			46,316
Share-based compensation expense	6,078		$ 1	6,077				6,078
Dividends declared on common stock and OP Units	(92,783)				(92,269)			(92,269)		(514)
Net income	$ 42,528				42,273			42,273		255
Balance at end of period (in shares) at Dec. 31, 2020	106,361,524		106,361,524
Balance at end of period at Dec. 31, 2020	$ 1,581,948		$ 1,064	1,688,540	(77,665)		(37,181)	1,574,758		7,190
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issuance (in shares)			18,230,721
Common stock issuance	469,200		$ 182	469,018				469,200
Common stock withheld related to net share settlement of equity awards	(353)				(353)			(353)
Costs related to issuance of common stock	(12,153)			(12,153)				(12,153)
Other comprehensive income (loss)	22,508						22,395	22,395		113
Share-based compensation expense (in shares)			56,808
Share-based compensation expense	5,683			5,683				5,683
Dividends declared on common stock and OP Units	(119,241)				(118,689)			(118,689)		(552)
Net income	$ 96,211				95,725			95,725		486
Balance at end of period (in shares) at Dec. 31, 2021	124,649,053		124,649,053
Balance at end of period at Dec. 31, 2021	$ 2,043,803		$ 1,246	$ 2,151,088	$ (100,982)		$ (14,786)	$ 2,036,566		$ 7,237